Resources
Get helpful information about MRD and M-inSight®
All
Articles
Documentation
Events
Posters
Publications
An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and MRD monitoring in MM patients - CCLM 2024
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator - CCLM 2024
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020
IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020
Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma - J Hematol Oncol. 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration - Clin Cancer Res. 2021
Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications - Front Oncol. 2022
